[{"id":"a9b98e89-64a8-4245-99e7-c014eaeac52a","acronym":"KEYNOTE-B59","url":"https://clinicaltrials.gov/study/NCT04977453","created_at":"2024-02-20T21:30:41.481Z","updated_at":"2025-02-25T16:16:30.492Z","phase":"Phase 1/2","brief_title":"GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04977453 - KEYNOTE-B59","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • efdelikofusp alfa (GI-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-09-19"}]